RxDoctor Payments Data

Ahsan Iqbal, MD

Rheumatology · Albuquerque, NMNPI 1710328398

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Amgen at 41.5% of the total. 2025 is the largest year on record at $1,592, 6.2 times the $259 reported in 2022.

$3,367in general payments, 2019–2025

Across 188 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$865
  • Pfizer$353
  • UCB, Inc.$316
  • AstraZeneca$153
  • Johnson & Johnson$127
  • plus $154 from 4 others

What the payments were for

  • Food & beverage$3,367100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,367 in reported general payments places this provider in the 65th percentile of 44 rheumatology providers in New Mexico.

See all rheumatology providers in New Mexico

Medicare billing

Part B allowed, 2024
$11,013
Medicare patients
70
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab57$414,129
BenlystaBelimumab17$101,163
Enbrel SureclickEtanercept13$95,714
Humira PenAdalimumab11$74,060
Mycophenolate Mofetil42$12,466
Hydroxychloroquine Sulfate91$3,814
Celecoxib91$2,914
MethotrexateMethotrexate Sodium95$2,443
Diclofenac Sodium30$447
Leflunomide13$379
Prednisone37$361
Allopurinol19$185
Methylprednisolone29$131
Folic Acid11$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBenlysta$20$101,16317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 44 rheumatology providers in New Mexico.

Other rheumatology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →